GlassScriptPhysician profile
Sara Karjoo
NPI 1457557761
$43,363.73
in general payments reported to CMS, 2019-2025
17 companies · $3,835 in 2025
The $3,835 reported for 2025 was more than what 89% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $148 · 2021: $93.51 · 2022: $78.31 · 2023: $15K · 2024: $23K · 2025: $3,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $9,820 · Honoraria: $3,320 · Food and Beverage: $2,325 · Travel and Lodging: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,384.00 |
| Consulting Fee | $9,820.00 |
| Honoraria | $3,320.00 |
| Food and Beverage | $2,325.04 |
| Travel and Lodging | $1,678.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $30,698.66 | 2023-2025 | Bylvay, Iqirvo |
| Mirum Pharmaceuticals, INC. | $10,823.55 | 2023-2025 | Livmarli |
| Abbvie INC. | $501.83 | 2019-2023 | |
| Qol Medical, LLC | $408.46 | 2019-2024 | Sucraid, Sucraid |
| Abbott Laboratories | $374.26 | 2023 | |
| Medtronic, INC. | $157.98 | 2024 | Endoflip |
| Genzyme Corporation | $65.55 | 2024 | |
| Travere Therapeutics, INC. | $61.95 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $56.27 | 2023-2024 | Imcivree, Imcivree |
| Regeneron Healthcare Solutions, INC. | $47.96 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $46.82 | 2021 | |
| Coloplast Corp | $23.86 | 2023 | Peristeen |
| Alnylam Pharmaceuticals INC. | $22.68 | 2024 | Givlaari |
| Amgen INC. | $22.33 | 2022 | |
| Alcresta Therapeutics, INC. | $18.19 | 2024 | Relizorb |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.88 | 2023 | Linzess |
| Romark Laboratories, Lc | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Karjoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.